Filling process validation

Alert and action levels for each parameter in each area or critical utility will be established based on the results from validation testing, compendia requirements, and cGMPs. Area or room limits will be based on the environmental data collected during the validation of the aseptic filling process validation. Specific action plans will be developed for addressing excursions beyond alert and action limits for each area or utility. 

Process validation should address issues concerned with the mixing process, the filling process, and derived physical tests. 

Take 7 samples from each additional location to further assess each significant event, such as filling or emptying of hoppers and IBCs, start and end of the compression or filling process, and equipment shutdown. This may be accomplished by using process development batches, validation batches, or routine manufacturing batches for approved products. 

As discussed, the manufacture of suspensions presents additional problems, particularly in the area of uniformity. The development data should address the key compounding and filling steps that ensure uniformity. The protocol should provide for the key in-process and finished product tests, along with their specifications. For oral solutions, bioequivalency studies may not always be needed. However, oral suspensions, with the possible exception of some of the over-the-counter antacids, usually require a bioequivalency or clinical study to demonstrate their effectiveness. Comparison of product batches with the biobatch is an important part of the validation process. Make sure there are properly written protocol and process validation reports and, if appropriate, data for comparing full-scale batches with biobatch available during FDA inspection. 

Process validation Inspection of the establishment to determine compliance with cGMP requirements and adherence to application requirements is a Field responsibility. CDER may request data to support validation of sterile processing operations for example, environmental monitoring, equipment validation, sterile fill validation, and associated sterile operations. 

Description of process validated load containing filling equipment and accessories not to exceed 102 kg Temperature set point for validation 121.0°C Temperature range for validation +0.5°C Cycle validated 35 min Validation records stored in archives A105-11 Revalidation records stored in archives C314-70... 

Aseptic fill processes are validated by simulating production conditions and using a bacterial culture medium as the product. This process simulation test is commonly referred to as a media fill. ... 

The PQ is the phase in which either a technical system is tested over a long period of time (e.g., water system), or a complex technical system is tested overall (connected filling line). For many systems OQ is the last phase performed during qualification. If there are only a few performance tests needed, it might be more practical to include them during OQ or process validation. Combining OQ and PQ decreases the number of documents (less documentation work in the future) and cuts approval time and effort. Again, the procedure for PQ is the same as for IQ and OQ ([develop PQ protocols, approve PQ protocols (by the quality assurance, production, and technical departments), perform PQ, work out the PQ report, and approve the PQ report (by the quality assurance, production, and technical departments)]. The documentation and test description are identical to those in the OQ phase. 

Validation of Aseptic Drug Powder Filling Processes Technical Report No. 6 PDA, Philadelphia, 1984. 

This approximation is valid when A. is much less than the linear dimension of the liquid volume, that is for pores with low curvature. Therefore, experimental relaxation rates from a system in the fast exchange limit can provide information on the ratios of the surface-to-bulk volumes of liquid, given the relaxation rates of surface and bulk liquid are known as well as the value for A. If relaxation values are acquired for different stages of filling, it is possible to determine details of the filling process, like the formation of puddles within the pore structure [Alll, Bool]. 

Process Validation (PV) verifies the performance of the overall product manufacturing process. PV is performed on the entire product manufacturing process, which includes all support, processes, preparation of media, components, buffers, formulation, filtration, filling, and packaging. 

Simulation trials (media fills) do not validate SALs for asepiieally filled products. The frequently encountered regulatory requirement for aseptic filling processes to be validated by simulation versus a standard of no more than 1 contaminated item in 1,000 items is not intended to imply that an SAL of 10 is satisfactory for these products. The SAL is a complex function of contamination rate and probability of survival the simulation trial measures only the first of these factors. SALs for aseptically filled products are in all likelihood much better than 10, only they are nonmeasureabie, and there is no basis or generally accepted theory to support extrapolation. 

The FDA has indicated [12] that it expects the same SALs for all supposedly sterile products irrespective of the method of manufacture, and that acceptable SALs should be no worse than 10. Practically, aseptic manufacturing systems are validated (see below) by establishing that each individual process is doing what it is supposed to do, and then integrating these systems by reference to a biological test, the media fill or simulation trial. Media fills determine an upper limit for SALs based on probabilities of contamination that may result from particular filling processes. Media fills provide no data on survival of microorganisms in products they do not therefore constitute a measure of product SALs. 

Arrangements 2 and 3 mockup the wet (sodium-filled process channels) and dry (empty process channels) control-rod concepts. Arrangement 4 was studied to check the validity of calculational techn ues for ui oi-soned, non-uniformly-loaded assemblies. 

A suppository filling machine enables a serial filling of large quantities of suppositories. The apparatus and its use are described in Sect. 28.7.2. A manually operated machine keeps the mass automatically homogeneous. The tap is operated manually as is the movement of the plastic suppository strips. An automatic machine fills the plastic molds automatically and often transits them too. The filling process of a suppository filling machine always has to be validated. The content of both the first and the last suppositories may not meet requirements. 

---